Pharma deals: Embracing disruptive technologies

The past 12 months of pharma dealmaking reflect a collective push into disruptive technologies with the power to create new drug markets and overhaul the way diseases are treated. Driven by a convergence of modality breakthroughs, a market turnaround, and an unprecedented case study on commercial success, it is clear that pharmas are looking externally for inroads into transformative technologies. 

In an analysis of the 221 licensing deals, research collaborations, and acquisitions signed by 21 top pharma companies between July 1, 2025 and June 30, 2026, a shift in the innovation focus from previous periods was apparent. ...